Navigation Links
First oral uveitis drug reduces both inflammation and recurrence in potentially blinding eye disease
Date:5/4/2009

eart disease, and diabetes. Mood disturbances are also associated with chronic corticosteroid use.

"The tapering of systemic corticosteroids to 5 mg or less per day, as implemented successfully in the LUMINATE studies, provides for additional safety from steroid morbidities," Dr. Rosenbaum commented.

"We are pleased with the demonstrated clinical effect of LX211 (Luveniq) in uveitis, coupled with what appears to be an acceptable side effect profile while reducing the need for systemic corticosteroid to half of the current guideline recommendation," commented Ulrich Grau, Ph.D., Lux Biosciences' President and Chief Executive Officer. "We're now pursuing regulatory filings, and if approved for commercialization by the appropriate regulatory agencies, LX211 would become the first agent in this class available in the United States and most other markets for the treatment of uveitis."

For more information on uveitis, its incidence, and how the disease is currently treated, please see http://www.luxbio.com/Uveitis%20Backgrounder.pdf

Overview of LUMINATE Trial Results

The LUMINATE program consists of three protocols that included 218 patients with active non-infectious uveitis with posterior (behind the lens of the eye) manifestation of the disease (LX211-01); 232 patients with clinically quiescent disease (LX211-02); and 108 patients with active uveitis with anterior (front of the eye) manifestation of the disease (LX211-03). Data from these trials showed:

  • Of the three doses studied, the 0.4 mg/kg BID dose had the most acceptable safety profile relative to effect on the disease. The adverse effects on the kidney (8.2% of subjects with decrease from baseline by ≥30% in glomerular filtration rate vs. 4.1 % in placebo) and blood pressure (mean increase in systolic BP by 6 mm Hg) will require monitoring, but were overall moderate and ma
    '/>"/>

Contact: Joan Kureczka
JKureczka@comcast.net
415-821-2413
Kureczka/Martin Associates
Source:Eurekalert

Page: 1 2 3 4

Related biology technology :

1. Novavax Announces Release Date of 2009 First Quarter, Financial Results and Investor Conference Call
2. Meso Scale Diagnostics Point of Care Influenza Test Led to the First Identification of A(H1N1) Swine Flu Infection
3. Medivation Announces First Quarter 2009 Financial Results Teleconference and Webcast on May 11, 2009
4. First H1N1 Swine Flu Vaccine, Replikins-Based, Is Ready Now for Testing Worldwide
5. Elsevier Health Sciences Appoints Dr. David Goldmann Editor-in-Chief of its First Consult Point of Care Resource
6. The first DFG research centers to be funded for another 4 years
7. TorreyPines Therapeutics Reports First Quarter 2009 Financial Results
8. Biotech Drops on Weaker First Quarter Drug Sales, But Broader Markets Remain on a Roll
9. First Patient Dosed in Phase I Clinical Trial of Tigris Pharmaceuticals GGTI-2418
10. United Therapeutics Reports First Quarter 2009 Financial Results
11. WuXi PharmaTech Schedules First-Quarter 2009 Earnings Release
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 2015 According to a new ... Modeling, PB/PK, PKPD, Trial Design, Toxicity Prediction, In-house, Contract ... Trial), by End Users - Global Forecast to 2020", ... reach USD 2,107.99 million by 2020 from USD 1,034.93 ... Browse more than 75 ...
(Date:7/30/2015)...  With over 60,000 customers across the globe, ISN improves the efficiency and effectiveness ... more than 60,000 safe and reliable contractors in over 80 countries. ... ... Over 60,000 Worldwide Customers In ... Headquartered in Dallas, TX , ISN has additional ...
(Date:7/30/2015)... ... 2015 , ... As part of its 2015 growth plan and as a follow up to ... business units, Whitehouse Laboratories is pleased to announce that it has begun construction on a ... Excellence and will be strictly dedicated to basic USP 51, USP 61, and USP 62 ...
(Date:7/29/2015)... , July 30, 2015 According to ... - Growth, Trends & Forecasts (2015-2020), , published by Mordor ... 30.25 billion by the end of 2020, with ... for more than 40% of the global market size. The ... a CAGR of 13.7% during the period of (2015-2020). ...
Breaking Biology Technology:Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3Whitehouse Labs Formally Announces Plans to Open a Microbiological Laboratory 2Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 2Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 3
... 27 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY ... Chief Executive Officer, will present at the 5th Annual ... September 28, 2010, at 10:30 a.m. Eastern Time. ... presentations will be accessible by visiting the Oncothyreon website ...
... Experience in STEMI Patients.... -- WASHINGTON, September 24, 2010 ... ... ... first_result; // Results are keyed by longUrl, so we need to grab the first one. for (var ...
... GeneLink BioSciences, Inc. (OTC Bulletin Board: GNLK, ... www.helixlife.com ), a private label distribution partnership serving the ... CEO, stated, "HelixLife gives GeneLink reach into new areas ... have not been available to us.  The HelixLife team ...
Cached Biology Technology:InspireMD Presents 2 Years Clinical Outcome of MGuard Multicenter Experience in STEMI Patients. The New Superb Clinical Results Were celebrated at InspireMD's TCT Satellite Symposium in Washington DC., Today. 2InspireMD Presents 2 Years Clinical Outcome of MGuard Multicenter Experience in STEMI Patients. The New Superb Clinical Results Were celebrated at InspireMD's TCT Satellite Symposium in Washington DC., Today. 3InspireMD Presents 2 Years Clinical Outcome of MGuard Multicenter Experience in STEMI Patients. The New Superb Clinical Results Were celebrated at InspireMD's TCT Satellite Symposium in Washington DC., Today. 4InspireMD Presents 2 Years Clinical Outcome of MGuard Multicenter Experience in STEMI Patients. The New Superb Clinical Results Were celebrated at InspireMD's TCT Satellite Symposium in Washington DC., Today. 5InspireMD Presents 2 Years Clinical Outcome of MGuard Multicenter Experience in STEMI Patients. The New Superb Clinical Results Were celebrated at InspireMD's TCT Satellite Symposium in Washington DC., Today. 6InspireMD Presents 2 Years Clinical Outcome of MGuard Multicenter Experience in STEMI Patients. The New Superb Clinical Results Were celebrated at InspireMD's TCT Satellite Symposium in Washington DC., Today. 7GeneLink Announces HelixLife Private Label Distribution Agreement 2
(Date:7/21/2015)... July 21, 2015 Passwords have proven ... in the recent U.S. Office of Personnel Management ... the infosec conundrum, but developers and end-users are ... address this dilemma, Biometrics-as-a-Service provider HYPR Corp. announced ... SDK for third party integration. ...
(Date:7/9/2015)... , July 07, 2015 ... the addition of the "Biometrics for Banking; ... 2015-2020" report to their offering. ... contributor to this growth and the forecast is ... in revenue for companies involved in delivering biometric ...
(Date:7/8/2015)... 8, 2015  Trovagene, Inc. (NASDAQ: TROV ... announced the launch of a study that aims ... Monitoring℠ (PCM) technology for predicting response to treatment ... combination of the novel immunotherapy agents Yervoy® (ipilumumab), ... inhibitor. The 50-patient study will be led by ...
Breaking Biology News(10 mins):HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
... . . Michael J. Ryan, Ph.D., a scientist at The ... a new horned dinosaur, Medusaceratops lokii . Approximately ... newly identified plant-eating dinosaur lived nearly 78 million years ago ... Its identification marks the discovery of a new genus ...
... Ardipithecus ramidus a purported human ancestor that was ... coming under fire from scientists who say there is scant ... at the African site where the creature lived 4.4 million ... savanna habitats," says University of Utah geochemist Thure Cerling, lead ...
... host a round-the-clock, robotically choreographed hunt for carbon-hungry materials. ... diverse team of scientists whose goal is to quickly ... a power plant,s exhaust, before it leaves the smokestack ... a recently discovered class of materials called metal-organic frameworks ...
Cached Biology News:Cleveland Museum of Natural History scientist announces new horned dinosaur 2Cleveland Museum of Natural History scientist announces new horned dinosaur 3Out of the woods for 'Ardi' 2Out of the woods for 'Ardi' 3Out of the woods for 'Ardi' 4The search for improved carbon sponges picks up speed 2The search for improved carbon sponges picks up speed 3
... For the professional, student, or faculty researcher, ... will accelerate your research and improve the quality ... data is the edge that researchers using LI-COR ... 10 years. The 4300 System is a third ...
This free-standing work station safely ventilates fumes upwards, away from the work surface. Optional Exhaust Purification System features bonded charcoal filters that remove organic chemical vapors ...
... biocompatibility testing at various temperatures, this ... through a clean heating unit to ... to 140F. Transparent panels allow full ... easy access to the work area. ...
... Tracker Intracellular Localization Kit with TransIT-siQUEST ... approach to directly label and deliver ... efficient yet non-destructive manner, for in ... functional inhibition of target gene expression ...
Biology Products: